The National Institute for Health and Care Excellence (NICE) has published its second set of rapid guidelines to cover the provision of radiotherapy services and bone marrow transplant during the COVID-19 pandemic.
Magenta’s stem cell therapy MGTA-456 met efficacy targets in the first few patients enrolled in a phase 2 trial to be presented at ASH next month, but with a question about safety.